Our Programs

Sardocor, Medera’s subsidiary, is dedicated to the clinical development of novel therapies for patients with incurable diseases.

Building upon Novoheart’s bioengineered human tissue-based assays for disease modelling and drug discovery, Sardocor aspires to create the shortest regulatory path to the clinic for advancing effective next-generation cell & gene therapy.

Pipeline

Medera’s Sardocor has 15 pre-clinical and 10 clinical programs in the pipeline. With the mini-Life Platform, the total number of novel pre-clinical candidates is expected to continue to grow as existing ones advance to the clinical stages.

Our Targeted Organ Systems